Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.00) by 5 percent. This is a 82.69 percent decrease over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $2.061 million which missed the analyst consensus estimate of $7.233 million by 71.51 percent. This is a 92.99 percent decrease over sales of $29.382 million the same period last year.